Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1247

Shown on this page

Current sort

Stored official records

Conditions: Brain Injuries, Traumatic
Interventions: ICP + PbtO2 guided management strategy, ICP guided management strategy; Other
Lead sponsor: University of Michigan; Other
Eligibility: 14 Years and older
Enrollment: 1,094 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 48
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 38 more

Conditions: Bicuspid Aortic Valve
Interventions: Medtronic TAVR Systems; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 25
States / cities: Phoenix, Arizona • La Jolla, California • Thousand Oaks, California + 21 more

Conditions: B Cell Malignancies, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: ABBV-525; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 10 more

Conditions: Primary Biliary Cirrhosis
Interventions: Seladelpar 10 mg Capsule, Seladelpar 5 mg Capsule; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 40
States / cities: Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Efgartigimod IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more

Conditions: HIV-1-infection
Interventions: B/F/TAF, ISL/LEN, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis
Interventions: Pacritinib, Physician's Choice medications; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more

Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Placebo, Tarlatamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 13 more

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 15 mg, ZT-01, 22 mg, ZT-01, 7 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Alcohol Associated Liver Disease, Alcohol Use Disorder, Behavioral Medicine, Medication Adherence, Medications for Alcohol Use Disorder
Interventions: AcamproSync; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 132
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more

Conditions: Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities, Peripheral Arterial Disease
Interventions: Plain (Uncoated) Balloon Angioplasty (PTA), SELUTION SLR™ DEB 014; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 30
States / cities: Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 26 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Stored official records

Brain Oxygen Optimization in Severe TBI, Phase 3

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

SELUTION4BTK Trial

About this Yale institution page